Haplotypes and a novel defective allele of CES2 found in a Japanese population

Drug Metabolism and Disposition

Volumn 35, Issue 10, 2007, Pages 1865-1872

  Kim, Su Ryang ^a   Sai, Kimie ^a   Tanaka Kagawa, Toshiko ^a   Jinno, Hideto ^a   Ozawa, Shogo ^a   Kaniwa, Nahoko ^a   Saito, Yoshiro ^a   Akasawa, Akira ^c   Matsumoto, Kenji ^b   Saito, Hirohisa ^b   Kamatani, Naoyuki ^d   Shirao, Kuniaki ^e   Yamamoto, Noboru ^e   Yoshida, Teruhiko ^f   Minami, Hironobu ^g   Ohtsu, Atsushi ^g   Saijo, Nagahiro ^g   Sawada, Jun Ichi ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; CARBOXYLESTERASE; CARBOXYLESTERASE 2; ESTER; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; SERINE PROTEINASE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CELL STRAIN COS1; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ASSAY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; INTRON; JAPANESE; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PLASMID; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS;

ALLELES; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASIAN CONTINENTAL ANCESTRY GROUP; CAMPTOTHECIN; CARBOXYLESTERASE; CERCOPITHECUS AETHIOPS; COS CELLS; HAPLOTYPES; HUMANS; HYPERSENSITIVITY; LINKAGE DISEQUILIBRIUM; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRODRUGS; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA;

EID: 34748886781     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.015339     Document Type: Article

References (32)

1. Bencharit S, Morton CL, Howard-Williams EL, Danks MK, Potter PM, and Pedinbo MR (2002) Structural insight into CPT-11 activation by mammalian carboxylesterases. Nat Struct Biol 9:337-342.
2. Cecchin E, Corona G, Masier S, Biason P, Cattarossi G, Frustaci S, Buonadonna A, Colussi A, and Toffoli G (2005) Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. Clin Cancer Res 11:6901-6907.
3. Charasson V, Bellott R, Meynard D, Longy M, Gorry P, and Robert J (2004) Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 76:528-535.
4. Dodds HM, Haaz MC, Riou JF, Robert J, and Rivory LP (1998) Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J Pharmacol Exp Ther 286:578-583.
5. Frank J, McGrath JA, Poh-Fitzpatrick MB, Hawk JL, and Christiano AM (1999) Mutations in the translation initiation codon of the protoporphyrinogen oxidase gene underlie variegate porphyria. Clin Exp Dermatol 24:296-301.
6. Fukao T, Matsuo N, Zhang GX, Urasawa R, Kubo T, Kohno Y, and Kondo N (2003) Single base substitutions at the initiator codon in the mitochondrial acetoacetyl-CoA thiolase (ACAT1/T2) gene result in production of varying amounts of wild-type T2 polypeptide. Hum Mutat 21:587-592.
7. Hanioka N, Jinno H, Nishimura T, Ando M, Ozawa S, and Sawada J (2001) High-performance liquid chromatographic assay for glucuronidation activity of 7-ethyl-10-hydroxycamptothecin (SN-38), the active metabolite of irinotecan (CPT-11), in human liver microsomes. Biomed Chromatogr 15:328-333.
8. Humerickhouse R, Lohrbach K, Li L, Bosron WF, and Dolan ME (2000) Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60:1189-1192.
9. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, and Ratain MJ (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847-854.
10. Kim SR, Nakamura T, Saito Y, Sai K, Nakajima T, Saito H, Shirao K, Minami H, Ohtsu A, Yoshida T, et al. (2003) Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2). Drug Metab Pharmacokinet 18:327-332.
11. Kitamura Y, Moriguchi M, Kaneko H, Morisaki H, Morisaki T, Toyama K, and Kamatani N (2002) Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using the EM algorithm. Ann Hum Genet 66:183-193.
12. Kozak M (1991) An analysis of vertebrate mRNA sequences: intimations of translational control. J Cell Biol 115:887-903.
13. Kubo T, Kim SR, Sai K, Saito Y, Nakajima T, Matsumoto K, Saito H, Shirao K, Yamamoto N, Minami H, et al. (2005) Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (hCE-2). Drug Metab Dispos 33:1482-1487.
14. Langenhoven E, Warnich L, Thiart R, Rubinsztein DC, van der Westhuyzen DR, Marais AD, and Kotze MJ (1996) Two novel point mutations causing receptor-negative familial hypercholesterolemia in a South African Indian homozygote. Atherosclerosis 125:111-119.
15. Marsh S, Xiao M, Yu J, Ahluwalia R, Minton M, Freimuth RR, Kwok PY, and McLeod HL (2004) Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics 84:661-668.
16. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, and Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182-2194.
17. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, et al. (2007) Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 17:497-504.
18. Nebert DW (2000) Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology. Pharmacogenetics 10:279-290.
19. Pindel EV, Kedishvili NY, Abraham TL, Brzezinski MR, Zhang J, Dean RA, and Bosron WF (1997) Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. J Biol Chem 272:14769-14775.
20. Quinteiro C, Castro-Feijoo L, Loidi L, Barreiro J, de la Fuente M, Dominguez F, and Pombo M (2002) Novel mutation involving the translation initiation codon of the growth hormone receptor gene (GHR) in a patient with Laron syndrome. J Pediatr Endocrinol Metab 15:1041-1045.
21. Sai K, Kaniwa N, Ozawa S, and Sawada J (2002) An analytical method for irinotecan (CPT-11) and its metabolites using a high-performance liquid chromatography: parallel detection with fluorescence and mass spectrometry. Biomed Chromatogr 16:209-218.
22. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, Hasegawa R, Kaniwa N, Sawada J, Komamura K, et al. (2004) UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 75:501-515.
23. Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse ML, Boige V, Gouyette A, et al. (2000) Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 6:2012-2020.
24. Satoh T and Hosokawa M (1998) The mammalian carboxylesterases: from molecules to functions. Annu Rev Pharmacol Toxicol 38:257-288.
25. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, and LaDu BN (2002) Current progress on esterases: from molecular structure to function. Drug Metab Dispos 30:488-493.
26. Schwer H, Langmann T, Daig R, Becker A, Aslanidis C, and Schmit G (1997) Molecular cloning and characterization of a novel putative carboxylesterase, present in human intestine and liver. Biochem Biophys Res Commun 233:117-120.
27. Shibata F, Takagi Y, Kitajima M, Kuroda T, and Omura T (1993) Molecular cloning and characterization of a human carboxylesterase gene. Genomics 17:76-82.
28. Takai S, Matsuda A, Usami Y, Adachi T, Sugiyama T, Katagiri Y, Tatematsu M, and Hirano K (1997) Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver. Biol Pharm Bull 20:869-873.
29. Wu MH, Chen P, Remo BF, Cook EH Jr, Das S, and Dolan ME (2003) Characterization of multiple promoters in the human carboxylesterase 2 gene. Pharmacogenetics 13:425-435.
30. Wu MH, Chen P, Wu X, Liu W, Strom S, Das S, Cook EH Jr, Rosner GL, and Dolan ME (2004) Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene. Pharmacogenetics 14:595-605.
31. Xie M, Yang D, Liu L, Xue B, and Yan B (2002) Human and rodent carboxylesterases: immunorelated-ness, overlapping substrate specificity, differential sensitivity to serine enzyme inhibitors, and tumor-related expression. Drug Metab Dispos 30:541-547.
32. Xu G, Zhang W, Ma MK, and McLeod HL (2002) Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8:2605-2611.